Looking for cjc 1295 dac acheter en ligne for laboratory experimentation? Researchers requiring high-purity, verified CJC-1295 DAC can source analytical-grade compounds directly from PX1 Research. Every lot undergoes rigorous RP-HPLC and Mass Spectrometry testing, accompanied by full third-party COAs to guarantee batch consistency and structural integrity for in vitro and preclinical research applications.
Looking for cjc 1295 dac acheter en ligne for laboratory experimentation? Researchers requiring high-purity, verified CJC-1295 DAC can source analytical-grade compounds directly from PX1 Research. Every lot undergoes rigorous RP-HPLC and Mass Spectrometry testing, accompanied by full third-party COAs to guarantee batch consistency and structural integrity for in vitro and preclinical research applications.
When evaluating options for cjc 1295 dac acheter en ligne, principal investigators and laboratory technicians must prioritize verified purity, analytical transparency, and standardized manufacturing. CJC-1295 DAC (Drug Affinity Complex) is a synthetic 30-amino acid peptide analog of Growth Hormone-Releasing Hormone (GHRH) modified to extend its biological half-life. Sourcing this compound online for experimental trials requires strict adherence to analytical quality control to ensure reproducible research outcomes.
PX1 Research provides laboratory-grade CJC-1295 DAC synthesized in GMP-compliant facilities within the United States. To meet the demanding criteria of modern biochemical research, every batch undergoes comprehensive testing via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (MS). Researchers can review lot-specific Certificates of Analysis (COAs) prior to acquisition, ensuring full visibility into sequence fidelity and purity levels exceeding 99%.
CJC-1295 with Drug Affinity Complex is structurally based on the first 29 amino acids of endogenous GHRH (Growth Hormone-Releasing Hormone), known as GHRH(1-29) or modified GRF 1-29. The insertion of a bi-functional chemical linker—specifically maleimidopropionic acid (MPA)—at the C-terminus of the peptide chain constitutes the defining feature of the Drug Affinity Complex (DAC) technology.
In vitro and preclinical models demonstrate that the MPA moiety reacts rapidly and covalently with free sulfhydryl groups on endogenous serum albumin after administration. By forming a stable bioconjugate with serum albumin, CJC-1295 DAC resists rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance. This structural modification extends the plasma half-life of the research peptide from several minutes to several days, permitting sustained receptor engagement in longitudinal GHRH analog research.
As a potent GHRH receptor agonist, CJC-1295 DAC selectively binds to the GHRH receptor (GHRHR) located on anterior pituitary somatotrope cells. Receptor binding activates the intracellular adenylate cyclase pathway, driving an elevation in cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) signaling cascades. This pathway stimulates both the transcription and exocytosis of growth hormone (GH).
Unlike native GHRH, which releases GH in short, pulsatile bursts, preclinical trials indicate that CJC-1295 DAC sustains baseline elevated GH levels while maintaining partial physiological pulsatility. Research models evaluating pituitary axis kinetics show that prolonged GHRHR stimulation induces sustained elevations in circulating total growth hormone without exhausting pituitary somatotrope reserves.
The primary downstream mediator of growth hormone activity is Insulin-like Growth Factor 1 (IGF-1), synthesized predominantly by hepatocytes in response to GH receptor activation. Preclinical rodent models investigating CJC-1295 DAC demonstrate significant, dose-dependent increases in circulating serum IGF-1 concentrations lasting up to 14 days following a single administration.
Because IGF-1 plays a critical role in cellular proliferation, protein synthesis, collagen deposition, and nitrogen retention, CJC-1295 DAC is frequently utilized in preclinical investigations focused on tissue repair, musculoskeletal regeneration, and metabolic modulation. Researchers examining the IGF-1 pathway mechanisms utilize this sustained agonist to measure long-term transcriptomic changes in muscle, tendon, and extracellular matrix tissues.
Navigating online suppliers requires objective criteria to filter out non-compliant or sub-standard materials. When assessing vendors for CJC-1295 DAC procurement, institutions should verify five critical quality control metrics:
1. Independent Testing: Analytical reports must originate from accredited ISO 17025 third-party testing laboratories, independent of the vendor's internal manufacturing setup. 2. RP-HPLC Purity Metrics: The chromatography report must confirm peak area purity of ≥99%, ruling out truncated peptide sequences or chemical impurities. 3. Mass Spectrometry Validation: MS identity verification confirms the observed molecular weight matches the theoretical mass of CJC-1295 DAC (3647.28 Da). 4. Endotoxin Content Analysis: Assays such as the Limulus Amebocyte Lysate (LAL) test must confirm endotoxin levels are well below established threshold limits (<0.1 EU/mg) to avoid cellular toxicity in cell cultures. 5. Domestic Manufacturing & Logistics: USA-based synthesis ensures compliance with strict quality standards, supported by reliable, temperature-controlled domestic distribution from state-of-the-art facilities.
When designing comparative secretagogue protocols, researchers often evaluate CJC-1295 DAC alongside other prominent peptides in the growth hormone secretagogue (GHS) and GHRH class. Understanding the kinetic differences between these structural variants is essential for selecting the optimal research tool.
For instance, CJC-1295 No DAC (also known as Mod GRF 1-29) lacks the maleimidopropionic acid linker. Consequently, it exhibits a brief half-life of approximately 30 minutes, simulating natural short-burst GH release when co-administered with ghrelin mimetics like Ipamorelin. In contrast, Sermorelin represents the truncated 29-amino-acid native sequence of GHRH, offering ultra-short receptor kinetics. Meanwhile, Tesamorelin features a trans-3-hexenoic acid modification tailored for lipid metabolism and hepatic fat reduction studies. CJC-1295 DAC remains unique among these options due to its extended half-life and sustained IGF-1 elevation profile.
Proper handling and storage of lyophilized CJC-1295 DAC are vital to maintaining peptide stability and preventing enzymatic or hydrolytic degradation. Upon receipt, unopened lyophilized vials should be stored in a freezer at -20°C to -80°C, protected from light and moisture.
To prepare the compound for in vitro assays, reconstitute the dry powder using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or standard laboratory-grade Sterile Water. Allow the solvent to flow gently down the inner glass wall of the vial rather than spraying directly onto the cake, then gently swirl until fully dissolved. Avoid vigorous agitation or vortexing, which can disrupt secondary structural conformation. Reconstituted solutions should be stored at 2°C to 8°C and utilized within defined experimental windows. For complete step-by-step procedures, consult our detailed peptide reconstitution guide.
Bacterial endotoxins (lipopolysaccharides) represent a significant confounding variable in cell culture and preclinical tissue studies. Presence of endotoxins can induce non-specific inflammatory responses, cytokine release, and altered gene expression in target tissues, invalidating analytical data.
At PX1 Research, every batch of CJC-1295 DAC is submitted to rigorous endotoxin testing via quantitative LAL assay protocols. By maintaining endotoxin concentrations below stringent threshold limits, PX1 Research guarantees that investigators receive pristine research compounds suitable for sensitive primary cell assays and animal model systems. Complete analytical test data can be reviewed in our publicly accessible research library.
Academic institutions, biotechnology firms, and contract research organizations (CROs) engaging in multi-phase research studies require consistent, scalable supply chains. Variations in peptide batch quality across study phases can introduce unquantifiable variance into longitudinal datasets.
PX1 Research maintains robust inventory reserves and offers specialized institutional support through our wholesale program. Qualified research facilities benefit from batch reservation options, lot-matching capabilities, dedicated account management, and standardized same-day dispatch from our dual distribution centers located in California and Arizona. This infrastructure ensures uninterrupted workflow for long-term experimental projects.
What is the key structural difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC contains a maleimidopropionic acid (MPA) linker bound to the C-terminus, forming the Drug Affinity Complex. This group covalently binds to circulating serum albumin, extending the half-life to several days. CJC-1295 No DAC lacks this linker and possesses a half-life of roughly 30 minutes.
What analytical tests are provided with CJC-1295 DAC from PX1 Research?
Every lot is supplied with a comprehensive third-party Certificate of Analysis (COA) containing Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity analysis, Mass Spectrometry (MS) for mass identification, and quantitative LAL endotoxin testing.
How should CJC-1295 DAC be stored prior to laboratory reconstitution?
Lyophilized CJC-1295 DAC should be stored in a desiccated environment at -20°C or below, away from direct light. Under these cold storage conditions, the dry peptide remains stable for extended periods.
What is the recommended solvent for reconstituting CJC-1295 DAC for research use?
Researchers typically reconstitute lyophilized CJC-1295 DAC using standard Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Water for injection depending on the specific downstream assay or in vitro application.
Is CJC-1295 DAC suitable for human consumption or clinical therapy?
No. CJC-1295 DAC supplied by PX1 Research is strictly designated for laboratory research use only. It is not intended for human consumption, clinical diagnostic purposes, or therapeutic use.
What receptor system does CJC-1295 DAC selectively target?
CJC-1295 DAC acts as a selective agonist at the GHRH receptor (GHRHR) on anterior pituitary somatotrope cells, activating intracellular adenylate cyclase and cAMP signaling pathways.
How does PX1 Research handle shipping for online peptide orders?
PX1 Research provides same-day dispatch for orders placed Monday through Friday before cut-off times, shipping directly from facilities in California and Arizona to maintain supply chain efficiency.
Can institutions purchase CJC-1295 DAC in bulk for extended research projects?
Yes, PX1 Research offers institutional accounts and bulk purchasing through our wholesale portal, supporting lot reservation and batch consistency across long-term experimental protocols.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.